Finance Watch: Three Neurology-Focused Firms Raise VC Mega-Rounds
With Neuron23, Westlake Unveils Second Start-Up In A Week
Executive Summary
Private Company Watch: Neuron23, Neurogene and Locanabio each raised $100m or more, highlighting increased investor interest in novel approaches to neurological diseases. Also, CRO dMed raised $100m and MinervaX brought in $57m for its vaccine to protect newborns.
You may also be interested in...
Finance Watch: Exo Raises $78m To Advance Exosite-Targeting Small Molecules
Also, Atlas Venture and Advent France Biotechnology raise new venture capital funds, Corium secures $235m in debt to commercialize ADHD drug and CBMG leads recent VC financings with $120m series A round.
Barry Greene Seizes CNS Leadership Opportunity As New Sage CEO
When Greene made the decision to leave Alnylam, he was interested in working with a drug maker treating central nervous system diseases.
Bristol’s Oral TYK2 Inhibitor Beats Amgen’s Otezla In Phase III
Bristol Myers Squibb released no detailed data from the first Phase III trial of deucravacitinib (BMS-986165) in psoriasis but said it achieved superiority to placebo and Otezla with safety similar to Phase II.